Trial · NCT07571148
Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
NCT07571148, Completed, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users. Trials, record NCT07571148. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07571148
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
- NCT number
- NCT07571148
- Status
- Completed
- Enrollment
- 6,876 participants, actual
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Schizophrenia
- Interventions
- KarXT (xanomeline and trospium)
- First posted
- 2026-05-06
- Last updated
- 2026-10-01
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of all-cause and schizophrenia-related healthcare encounters per participant | Baseline and up to 6 months | Number of inpatient admissions, emergency room visits, urgent care visits, and outpatient visits identified from claims and EHR data. Schizophrenia-related encounters are defined as those with a primary diagnosis of schizophrenia using ICD-10-CM codes. |
| Primary | Number of participants adherent to KarXT (proportion of days covered ≥80%) | Baseline and up to 6 months | Adherence measured using proportion of days covered (PDC), defined as total days of KarXT supply divided by total number of days in the follow-up period. Participants with PDC ≥80% are classified as adherent. Reported as number and percentage of participants meeting adherence criteria. |
| Primary | Time to discontinuation of KarXT | Baseline and up to 6 months | Time from index date (first KarXT prescription) to discontinuation, defined as a gap of ≥45 consecutive days without KarXT supply. |
| Primary | KarXT initial dose (index dose) | Baseline | Distribution of index dose (50 mg/20 mg, 100 mg/20 mg, 125 mg/30 mg, or starter pack) |
| Primary | Number of of participants with dose increases or decreases | Baseline and up to 6 months | |
| Primary | Number of participants using concomitant antipsychotic and anticholinergic medications | Baseline and up to 6 months | |
| Primary | Number of participants with comorbidities | Baseline and up to 6 months | |
| Primary | Number of participants with gastrointestinal adverse events | Baseline and up to 6 months | |
| Primary | Number of participants with documented schizophrenia symptoms | Baseline and up to 6 months | Presence of positive and negative schizophrenia symptoms identified using natural language processing (NLP) of unstructured clinical notes, including hallucinations, delusions, disorganized thought, amotivation, avolition, anhedonia, asociality, alogia, and blunted affect. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07571148
GET https://conductscience.org/api/trials/v1/NCT07571148/registered